alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Plasma and spinal-fluid biomarkers

1,573 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2020-07-28 Tau biomarkers

    We included 201 individuals (mean age 73.5 years, mean BMI 27.4 kg/m2).

  2. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Clinical chemistry 2020-04-01 Biomarkers

    CRM-adjusted Aβ42 calibrator concentrations were calculated using the regression equation Y (CRM-adjusted) = 0.89X (calibrators) + 32.6.

  3. Neuroinflammation and protein aggregation co-localize across the frontotemporal dementia spectrum

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Brain : a journal of neurology 2020-03-01 Brain scans and imaging

    We found significant group-wise differences in 11C-PK-11195 binding between each patient group and controls in frontotemporal regions, in both a regions-of-interest analysis and in the comparison of principal spatial components of binding. 18F-AV-1451 binding was increased in semantic variant primary progressive aphasia compared to controls in the temporal regions, and both semantic variant primary progressive aphasia and behavioural variant frontotemporal dementia differed from controls in the expression of principal spatial components of binding, across temporal and frontotemporal cortex, respectively.

  4. Cerebrospinal Fluid and MRI Biomarkers in Neurodegenerative Diseases: A Retrospective Memory Clinic-Based Study

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of Alzheimer's disease : JAD 2020 Tau biomarkers

    Numerous imaging variables differed by clinical diagnosis, including hippocampal, amygdalar and inferior lateral ventricular volumes and entorhinal, lingual, inferior parietal and isthmus cingulate cortical thicknesses, at a false discovery rate (FDR)-corrected threshold for significance (analysis of covariance; p < 0.005).

  5. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's research & therapy 2019-12-01 Biomarkers

    Plasma TP42/40 ratio showed a relevant and significant potential as a screening tool to identify brain Aβ positivity in preclinical and prodromal stages of Alzheimer's disease.

  6. Lower CSF Amyloid-Beta1-42 Predicts a Higher Mortality Rate in Frontotemporal Dementia

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Diagnostics (Basel, Switzerland) 2019-10-25 Tau biomarkers

    Frontotemporal lobar degeneration, the neuropathological substrate of frontotemporal dementia (FTD), is characterized by the deposition of protein aggregates, including tau.

  7. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's research & therapy 2019-03-21 Brain scans and imaging

    All Centiloid cut-offs fell within the range of 25-35, except for CSF Aβ42 that rendered an optimal cut-off value of 12 CL.

  8. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Clinica chimica acta; international journal of clinical chemistry 2019-03-04 Biomarkers

    The cerebrospinal fluid (CSF) signature of Alzheimer's disease (AD) includes abnormal levels of amyloid-β 1-42 (Aβ42), total tau (t-Tau) and phosphorylated tau (p-Tau).

  9. AMYPAD Diagnostic and Patient Management Study: Rationale and design

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2018-10-16 Brain scans and imaging

    Reimbursement of amyloid-positron emission tomography (PET) is lagging due to the lack of definitive evidence on its clinical utility and cost-effectiveness.

  10. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2018-07-02 Biomarkers

    Up to four freeze-thaw cycles do not influence single molecule array blood biomarkers of neurofilament light chain, total tau, or Aβ 42 , with at most minor reductions in Aβ 40 .

  11. Amyloid blood biomarker detects Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. EMBO molecular medicine 2018-05-01 Biomarkers

    Alzheimer's disease (AD) is currently incurable, but there is general agreement that a minimally invasive blood biomarker for screening in preclinical stages would be crucial for future therapy.

  12. FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Brain : a journal of neurology 2018-04-01 Brain scans and imaging

    Age-related hippocampal sclerosis may account for a significant proportion of elderly participants with amnestic dementia.

  13. Prognostic value of amyloid PET scan in normal pressure hydrocephalus

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology 2017-11-11 Brain scans and imaging

    Amyloid positron emission tomography ([18F] florbetaben (FBB) PET) can be used to determine concomitant Alzheimer's disease (AD) in idiopathic normal pressure hydrocephalus (iNPH) patients.

  14. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Brain : a journal of neurology 2017-03-01 Brain scans and imaging

    More specifically, 18F-AV-1451 binding was significantly increased in patients with Alzheimer's disease, relative to patients with progressive supranuclear palsy and with control subjects, in the hippocampus and in occipital, parietal, temporal, and frontal cortices (t's > 2.2, P's < 0.04).

  15. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Brain 2017-02-15 Brain scans and imaging

    See Vandenberghe and Schaeverbeke (doi:10.1093/awx065) for a scientific commentary on this article.

  16. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Brain, behavior, and immunity 2017-02-01 Biomarkers

    Studies on markers of inflammation in subjects with mild cognitive impairment or AD dementia provided inconsistent results.

  17. Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2017-01-23 Brain scans and imaging

    Based on retrospective data, we develop personalized risk estimates for MCI patients.

  18. Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of Alzheimer's disease : JAD 2016-03-01 Biomarkers

    Increasingly, clinical trials for Alzheimer's disease (AD) are being conducted earlier in the disease phase and with biomarker confirmation using in vivo amyloid PET imaging or CSF tau and Aβ measures to quantify pathology.

  19. Cerebrospinal fluid profiles with increasing number of cerebral microbleeds in a continuum of cognitive impairment

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2015-09-30 Tau biomarkers

    Cerebral microbleeds (CMBs) are hypothesised to have an important yet unknown role in the dementia disease pathology.

  20. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's research & therapy 2015-06-01 Biomarkers

    In patients with a discrepancy between CSF p-tau181 and CSF Aβ42, the assessment of Aβ 42/40 ratio led to a reliable biological conclusion in over 50% of cases that agreed with a clinician's diagnosis.

  21. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-04-24 Tau biomarkers

    In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios.

  22. Reduced plasma desmosterol-to-cholesterol ratio and longitudinal cognitive decline in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2015-03-29 Biomarkers

    Plasma DES/CHO was significantly reduced in Japanese AD patients and significantly correlated with Mini-Mental State Examination (MMSE) score.

  23. Tau PET imaging in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Current neurology and neuroscience reports 2014-11-01 Brain scans and imaging

    In several neurodegenerative diseases that are collectively called tauopathies, progressive accumulation of tau in the brain is closely associated with neurodegeneration and cognitive impairment.

  24. Accurate automatic estimation of total intracranial volume: a nuisance variable with less nuisance

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. NeuroImage 2014-10-01 Brain scans and imaging

    Total intracranial volume (TIV/ICV) is an important covariate for volumetric analyses of the brain and brain regions, especially in the study of neurodegenerative diseases, where it can provide a proxy of maximum pre-morbid brain volume.

  25. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2013-11-05 Brain scans and imaging

    Major imaging biomarkers of Alzheimer's disease include amyloid deposition [imaged with [(11)C]Pittsburgh compound B (PiB) PET], altered glucose metabolism (imaged with [(18)F]fluro-deoxyglucose PET), and structural atrophy (imaged by MRI).

From across this topic

10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics